Detalles de la búsqueda
1.
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Lancet
; 397(10275): 671-681, 2021 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33545094
2.
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Lancet
; 396(10255): 887-897, 2020 09 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32896291
3.
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19.
Front Immunol
; 14: 1129245, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37063833
4.
Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection.
Viruses
; 14(11)2022 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36366583
5.
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.
Front Immunol
; 13: 822159, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35281053
6.
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults.
Lancet Reg Health Eur
; 11: 100241, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34746910
Resultados
1 -
6
de 6
1
Próxima >
>>